Breathless Heart Only When the Neck Is Deep in Water?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. by Emdin, Michele et al.
to
g
o
e
l
Journal of the American College of Cardiology Vol. 61, No. 11, 2013
© 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.021EDITORIAL COMMENT
Breathless Heart
Only When the Neck
Is Deep in Water?*
Michele Emdin, MD, PHD,†
Claudio Passino, MD,†‡
Alberto Giannoni, MD, PHD†
Pisa, Italy
Thirty-six years after the accurate clinical description of
periodic breathing by Cheyne in 1818, William Stokes was
the first physician to link a similar observation to heart
failure (HF): “There is a symptom which appears to belong
to a weakened state of the heart, and which, therefore, may
be looked for . . . It consists in the occurrence of a series of
inspirations, increasing to a maximum, and then declining
in force and length, until a state of apparent apnoea is
established . . . I have only seen during a few weeks previous
o the death of the patient . . . ” (1).
See page 1157
His message is still factual; periodic breathing, associated
with repetitive central hyperpneas and apneas and/or hy-
popneas (2), “may be looked for” in HF patients, as a part of
comprehensive diagnostic workup and risk stratification.
The phenomenon, which has been extensively studied over
recent years (2), appears to be a pure consequence of HF
syndrome, occurring in up to 40% of patients with either
systolic or diastolic dysfunction, despite therapy according
to current guidelines. Several studies confirm that apnea not
only happens during sleep in HF patients, but also occurs
frequently during wakefulness (3,4), as originally described
by Cheyne and Stokes, and even in upright positions (3).
Apnea severity is considered a risk marker and/or factor,
because it contributes, via sympathetic activation (4,5) and
worsening of hemodynamics (6), to disease evolution, life-
threatening arrhythmias, and fatal outcome (2). This was
demonstrated in the presence of either central sleep apneas
(CSA), with high values of the apnea-hypopnea index (7),
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paper to disclose.or in central apneas during wakefulness (3,4). As an alter-
native interpretation, central apneas have been regarded as a
compensatory response, because of positive physiological
effects associated with the hyperpneic phase of the cycle,
such as amelioration of gas exchange (for increased end-
expiratory lung volume), desirable respiratory alkalosis, lytic
effect on sympathetic activation, and improved bronchial
patency (8).
Obstructive sleep apneas (OSA) may be present before
HF (9) and are associated with risky clinical conditions,
such as obesity and arterial hypertension. Furthermore,
OSA is frequent in HF patients (10), contributing to disease
progression and increased mortality by inducing intermit-
tent hypoxia, oxidative stress, sympathetic overactivation,
and exaggerated negative intrathoracic pressure with left
ventricular afterload and reduced cardiac output (11).
HF patients with predominant CSA are mainly male and
older, and have lower body mass indexes (11) and higher
pulmonary capillary wedge pressures (6) than those with
predominant OSA. However, OSA and CSA may coexist
in the same individual patient (12).
The pathophysiology of CSA in HF is complex; the main
mechanism is identified to be an enhanced peripheral
and/or central chemosensitivity (12,13), with apneas occur-
ring after intense hyperventilation, due to hypoxia and/or
hypercapnia. The circulatory delay between the lung and the
chemoreceptors, as well as a reduction in either oxygen or
carbon dioxide (CO2) lung stores may favor CSA mainte-
nance (12). Finally, lung congestion may also increase
ventilation instability via pulmonary J-receptors (6).
The pathogenesis of OSA (14) is likely influenced by
anatomic factors that reduce pharyngeal area, such as
hypoplastic or displaced skeletal structures and redundant
soft tissues. Functional factors can also affect OSA, includ-
ing fat accumulation, pharyngeal mucosal edema, and upper
airway dilator muscular dysfunction.
A remarkable effort to compare the pathophysiology of
OSA and CSA in HF has been recently performed by
Bradley et al. (15), leading to the hypothesis of a “unifying
pathway,” represented by the potential effects of rostral fluid
shift (15). In this line of research, the paper by Kasai et al.
(16) in this issue of the Journal explores a model resembling
overnight fluid shift, with patients in the supine position
and using lower body positive pressure (LBPP) caused by
inflation of antishock trousers. LBPP was found to increase
neck circumference in both OSA and CSA. However,
although it induced an increase in pharyngeal resistance, a
decrease in minute volume of ventilation, and an increase in
partial pressure of CO2 in the OSA-dominant group,
pposite findings were observed in the CSA-dominant
roup. This is explained by investigators to be the consequence
f an increased ventricular filling pressure in the CSA group,
choing back to pulmonary J-receptors, with increased venti-
atory drive. However, the size effect in rostral fluid shift in thesubsets and the potential confounders in the experimental
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Apneas and Heart Failure March 19, 2013:1167–8model should be further evaluated, such as chemoreflex stim-
ulation by CO2 shift from the peripheral venous system or
irect stimulation of leg metaboreceptors by compression.
The paper by Kasai et al. (16) is of great value because it
efines a novel mechanism, among several already de-
cribed, that underlays both OSA and CSA. However, CSA
nd OSA should be considered heterogeneous disorders,
ather than single entities. Given their multifactorial back-
round, it seems unlikely that a valid unique causal factor
an be identified in every HF patient.
This explains why all of the treatment strategies proposed
or either OSA and CSA in HF, including the maneuvers
roposed by the investigators to prevent “fluid accumulation
n the legs during the daytime or rostral fluid shift at night,”
e.g., intensive fluid unloading by diuretics), are only able to
lunt, but not erase, the apnea phenomenon (2,12).
Several issues still need to be addressed: what is the best
ndicator to identify those patients in whom CSA and/or
SA is a risk factor and deserve a specific treatment? Is the
ndicator the frequency of apneas (7), their daytime occur-
ence (3,4), the desaturation severity, the overall burden of
octurnal hypoxemia, the level of neurohormonal activation,
he objective evidence of increased chemosensitivity (17), or
combination of these?
As a concluding remark, we agree with Kasai et al. (16)
n the concept that a rational treatment would better
ounteract the pathophysiological triggers than targeting
sleep) apneas only. However, further comprehension of the
omplex interaction among the diverse, specific pathogenic
echanisms that lead to OSA and/or CSA may promote
he identification of those needing a targeted treatment and
he development of novel therapeutic strategies that could
e tailored according to the diagnosed underlying mecha-
isms in the individual patient.
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